Article thumbnail
Location of Repository

Characterization of HPV16 L1 loop domains in the formation of a type-specific, conformational epitope

By Vanessa A Olcese, Yan Chen, Richard Schlegel and Hang Yuan

Abstract

BACKGROUND: Virus-like particles (VLPs) formed by the human papillomavirus (HPV) L1 capsid protein are currently being tested in clinical trials as prophylactic vaccines against genital warts and cervical cancer. The efficacy of these vaccines is critically dependent upon L1 type-specific conformational epitopes. To investigate the molecular determinants of the HPV16 L1 conformational epitope recognized by monoclonal antibody 16A, we utilized a domain-swapping approach to generate a series of L1 proteins composed of a canine oral papillomavirus (COPV) L1 backbone containing different regions of HPV16 L1. RESULTS: Gross domain swaps, which did not alter the ability of L1 to assemble into VLPs, demonstrated that the L1 N-terminus encodes at least a component of the 16A antigenic determinant. Finer epitope mapping, using GST-L1 fusion proteins, mapped the 16A epitope to the L1 variable regions I and possibly II within the N-terminus. CONCLUSIONS: These results suggest that non-contiguous loop regions of L1 display critical components of a type-specific, conformational epitope

Topics: Research Article
Publisher: BioMed Central
Year: 2004
DOI identifier: 10.1186/1471-2180-4-29
OAI identifier: oai:pubmedcentral.nih.gov:499545
Provided by: PubMed Central

Suggested articles

Citations

  1. (1996). 3rd: Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11. J Virol
  2. (1997). A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera.
  3. (2001). Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops.
  4. (1997). Christensen ND: A neutralizing epitope of human papillomavirus type 11 is principally described by a continuous set of residues which overlap a distinct linear, surface-exposed epitope.
  5. (2002). Coursaget P: Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses.
  6. (2003). Coursaget P: Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduces their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope. Virology
  7. (1997). De Grandi P: Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun
  8. (2001). Der Vange N: Epidemiologic and mucosal immunologic aspects of HPV infection and HPV-related cervical neoplasia in the lower female genital tract: a review.
  9. (2001). DR: Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
  10. (2001). EL: Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection.
  11. (2000). Galloway DA: Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection.
  12. (1997). Generation and neutralization of pseudovirions of human papillomavirus type 33. J Virol
  13. (1995). Heyneker HL: Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides. Gene
  14. (2000). Hidesheim A: Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report.
  15. (2001). Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology
  16. (2001). Immunization with a pentameric L1 fusion protein protects against papillomavirus infection.
  17. (1996). Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus.
  18. (1990). JP: Distribution and specific identification of papillomavirus major capsid protein epitopes by immunocytochemistry and epitope scanning of synthetic peptides.
  19. (1996). JT: Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition.
  20. (2001). JT: Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies.
  21. (1996). JT: In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype.
  22. (1994). JT: Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins.
  23. (1997). Kirnbauer R: Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.
  24. (2002). KU: A controlled trial of a human papillomavirus type 16 vaccine.
  25. (1995). KV: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.
  26. (1996). Leiserowitz GS: Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology
  27. (1995). Lowy DR: Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.
  28. (1996). Lowy DR: Papillomavirus-like particles and HPV vaccine development. Semin Cancer Biol
  29. (2001). Ludmerer SW: A novel human papillomavirus type 6 neutralizing domain comprising two discrete regions of the major capsid protein l1. Virology
  30. (2003). McClements WL: Human papillomavirus type 6 virus-like particles present overlapping yet distinct conformational epitopes.
  31. (1998). Mutant canine oral papillomavirus L1 capsid proteins which form virus-like particles but lack native conformational epitopes.
  32. (2000). ND: HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain. Virology
  33. (1999). Papillomavirus-like particle vaccines for cervical cancer. Mol Med Today
  34. (1991). Pilacinski W: Identification of linear epitopes of the BPV-1 L1 protein recognized by sera of infected or immunized animals. Pathobiology
  35. (2001). RC: Immunological analyses of human papillomavirus capsids. Vaccine
  36. (1998). RD: Natural history of cervicovaginal papillomavirus infection in young women.
  37. (2001). Reichman RC: A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers.
  38. (1994). Reichman RC: Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles.
  39. (2001). RL: Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1.
  40. (2000). SC: Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell
  41. (1996). Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology
  42. (1999). Suzich JA: Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol
  43. (1995). Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.
  44. (1996). Viscidi RP: Self-assembly of in vitro-translated human papillomavirus type 16 L1 capsid protein into virus-like particles and antigenic reactivity of the protein. Clin Diagn Lab Immunol

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.